Press releases
- Novocure to Report Second Quarter 2024 Financial Results
- METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
- Novocure Reports First Quarter 2024 Financial Results
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
More ▼
Key statistics
As of last trade, Novocure Ltd (038:BER) traded at 17.29, 67.73% above the 52 week low of 10.31 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.32 |
---|---|
High | 17.33 |
Low | 17.29 |
Bid | 16.53 |
Offer | 18.04 |
Previous close | 17.28 |
Average volume | 174.56 |
---|---|
Shares outstanding | 107.61m |
Free float | 97.64m |
P/E (TTM) | -- |
Market cap | 2.06bn USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 10:00 BST.
More ▼